HC Wainwright & Co. Downgrades CymaBay Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce downgraded CymaBay Therapeutics (NASDAQ:CBAY) from Buy to Neutral.

February 13, 2024 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CymaBay Therapeutics was downgraded from Buy to Neutral by HC Wainwright & Co. analyst Ed Arce.
Analyst ratings often influence stock prices in the short term. A downgrade from Buy to Neutral suggests a less optimistic outlook on the stock by the analyst, which could lead to a decrease in investor confidence and potentially lower the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100